PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9210401-0	1997	Inhibition of the expression of ornithine decarboxylase and c-Myc by cell-permeant ceramide in difluoromethylornithine-resistant leukaemia cells.	Eflornithine	95-118	myelocytomatosis oncogene	Mus musculus	62-65	
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	myelocytomatosis oncogene	Mus musculus	166-169	
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	59-88	myelocytomatosis oncogene	Mus musculus	322-325	
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	myelocytomatosis oncogene	Mus musculus	166-169	
19147568-4	2009	Indeed, sustained treatment with the Odc suicide inhibitor alpha-difluoromethylornithine (DFMO) or Odc heterozygosity markedly impairs lymphoma development in Emicro-Myc transgenic mice, and these effects are linked to the induction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1), which is normally repressed by Myc.	Eflornithine	90-94	myelocytomatosis oncogene	Mus musculus	322-325	
15894264-4	2005	Moreover, lymphoma development was markedly delayed in E mu-Myc;Odc(+/-) transgenic mice and in E mu-Myc mice treated with the Odc inhibitor difluoromethylornithine (DFMO).	Eflornithine	141-164	myelocytomatosis oncogene	Mus musculus	101-104	
34947972-0	2021	DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.	Eflornithine	0-4	myelocytomatosis oncogene	Mus musculus	82-85	
34947972-5	2021	Here, we targeted KRAS, through inhibition of downstream c-RAF with GW5074, and MYC expression via difluoromethylornithine (DFMO).	Eflornithine	99-122	myelocytomatosis oncogene	Mus musculus	80-83	
34947972-5	2021	Here, we targeted KRAS, through inhibition of downstream c-RAF with GW5074, and MYC expression via difluoromethylornithine (DFMO).	Eflornithine	124-128	myelocytomatosis oncogene	Mus musculus	80-83	
34947972-9	2021	To further investigate, immunohistochemical staining showed DFMO diminished MYC expression and increased tumor infiltration of macrophages, CD86+ cells, CD4+ and CD8+ T lymphocytes.	Eflornithine	60-64	myelocytomatosis oncogene	Mus musculus	76-79	
34947972-11	2021	Collectively, this study highlights that in contrast to GW5074, the inhibition of MYC through DFMO may be an effective treatment modality to modulate PDAC immunosuppression.	Eflornithine	94-98	myelocytomatosis oncogene	Mus musculus	82-85